

Atrial Fibrillation Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/ABA4BA6EDC03EN.html>

Date: March 2022

Pages: 101

Price: US\$ 2,000.00 (Single User License)

ID: ABA4BA6EDC03EN

Abstracts

Atrial Fibrillation Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atrial Fibrillation - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Atrial Fibrillation (Cardiovascular) pipeline landscape.

Atrial fibrillation is an irregular and often rapid heart rate that commonly causes poor blood flow to the body. Symptoms include decreased blood pressure, weakness, lightheadedness, confusion and chest pain. The predisposing factors include age, heart disease, high blood pressure, family history and drinking alcohol. Treatments for atrial fibrillation may include medications and surgery.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atrial Fibrillation - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Atrial Fibrillation (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and

press releases.

The Atrial Fibrillation (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Atrial Fibrillation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 2, 3, 11, 4, 1, 11 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Atrial Fibrillation (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Atrial Fibrillation (Cardiovascular).

The pipeline guide reviews pipeline therapeutics for Atrial Fibrillation (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Atrial Fibrillation (Cardiovascular) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Atrial Fibrillation (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Atrial Fibrillation (Cardiovascular)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Atrial Fibrillation (Cardiovascular).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Atrial Fibrillation (Cardiovascular) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Atrial Fibrillation - Overview
- Atrial Fibrillation - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Atrial Fibrillation - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Atrial Fibrillation - Companies Involved in Therapeutics Development
- AbbVie Inc
- Acesion Pharma Aps
- Aetas Pharma Co Ltd
- AnaBios Corp
- Anthos Therapeutics Inc
- ARCA biopharma Inc
- Armaron Bio Pty Ltd
- Bayer AG
- Bristol-Myers Squibb Co
- Chaperone Pharma BV
- Chong Kun Dang Pharmaceutical Corp
- Correvio Pharma Corp
- Daiichi Sankyo Co Ltd
- Espero BioPharma Inc
- FB HRS LLC
- G3 Pharmaceuticals Inc
- Hanmi Pharmaceuticals Co Ltd
- HUYA Bioscience International LLC
- Hyloris Pharmaceuticals SA
- InCarda Therapeutics Inc
- Inomagen Therapeutics Inc
- Merck & Co Inc

Merz Pharma GmbH & Co KgaA

Milestone Pharmaceuticals Inc

Nissan Chemical Corp

Novartis AG

Rithim Biologics Inc

The Geneva Biotech Center SA

Toa Eiyo Ltd

Verseon Corp

Vivasc Therapeutics Inc

Atrial Fibrillation - Drug Profiles

abelacimab - Drug Profile

Product Description

Mechanism Of Action

History of Events

amiodarone - Drug Profile

Product Description

Mechanism Of Action

History of Events

AP-30663 - Drug Profile

Product Description

Mechanism Of Action

History of Events

asundexian - Drug Profile

Product Description

Mechanism Of Action

History of Events

bucindolol hydrochloride - Drug Profile

Product Description

Mechanism Of Action

History of Events

budiodarone - Drug Profile

Product Description

Mechanism Of Action

History of Events

CHAP-001 - Drug Profile

Product Description

Mechanism Of Action

History of Events

CKD-825 - Drug Profile

Product Description
Mechanism Of Action
History of Events
danicamtiv - Drug Profile
Product Description
Mechanism Of Action
History of Events
dofetilide - Drug Profile
Product Description
Mechanism Of Action
edoxaban tosylate - Drug Profile
Product Description
Mechanism Of Action
History of Events
etripamil - Drug Profile
Product Description
Mechanism Of Action
History of Events
FBHRS-001 - Drug Profile
Product Description
Mechanism Of Action
flecainide acetate - Drug Profile
Product Description
Mechanism Of Action
History of Events
GBCA-1 - Drug Profile
Product Description
Mechanism Of Action
History of Events
gemibotulinumtoxin A - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy for Atrial Fibrillation - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy for Post-Operative Atrial Fibrillation - Drug Profile
Product Description

Mechanism Of Action
HBI-3000 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HIP-2001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HSY-244 - Drug Profile
Product Description
Mechanism Of Action
History of Events
incobotulinumtoxin A - Drug Profile
Product Description
Mechanism Of Action
History of Events
M-201 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MK-1832 - Drug Profile
Product Description
Mechanism Of Action
NIP-151 - Drug Profile
Product Description
Mechanism Of Action
NP-202 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NTC-801 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules for Atrial Fibrillation - Drug Profile
Product Description
Mechanism Of Action
History of Events

Small Molecules to Block GIRK for Atrial Fibrillation - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit LGALS3 for Cardiovascular and Genito Urinary System

Disorders - Drug Profile

Product Description

Mechanism Of Action

TY-55348 - Drug Profile

Product Description

Mechanism Of Action

TY-55458 - Drug Profile

Product Description

Mechanism Of Action

VE-1902 - Drug Profile

Product Description

Mechanism Of Action

History of Events

vernakalant hydrochloride - Drug Profile

Product Description

Mechanism Of Action

History of Events

Atrial Fibrillation - Dormant Projects

Atrial Fibrillation - Discontinued Products

Atrial Fibrillation - Product Development Milestones

Featured News & Press Releases

Dec 07, 2021: Atrial Fibrillation clinical trial with novel dual activity factor XI agent completes enrollment

Nov 15, 2021: Milestone Pharmaceuticals announces presentation of heart rate analysis of NODE-301 trial of Etripamil in Patients with PSVT

Nov 02, 2021: HUYABIO International announces initiation of phase 2 atrial fibrillation trial

Aug 30, 2021: ENVISAGE-TAVI AF data published in The NEJM demonstrates edoxaban's noninferiority to VKAs in High-risk AF patients following successful heart valve procedure

Aug 28, 2021: New data support the use of LIXIANA (edoxaban) in complex patient populations with atrial fibrillation (AF)

Aug 28, 2021: Edoxaban may be effective treatment for atrial fibrillation after transcatheter aortic valve replacement

Jun 23, 2021: InCarda Therapeutics announces positive end-of-phase 2 meeting with

FDA for InRhythm for Treatment of atrial fibrillation

Jun 09, 2021: InCarda Therapeutics provides corporate update highlighting new phase 2 data for InRhythm program, plans for pivotal phase 3 study and expansion of senior management team

Apr 26, 2021: New two-years follow-up data from ETNA-AF-Europe reaffirms benefit of LIXIANA (edoxaban) in people with atrial fibrillation

Apr 21, 2021: Rhythm Therapeutics, awarded \$3.67 Million NIH SBIR fast track grant to develop gene therapy for atrial fibrillation

Mar 29, 2021: Milestone Pharmaceuticals announces first patient enrolled in the ReVeRA study, its phase 2 trial of Etripamil in atrial fibrillation and rapid ventricular rate

Jan 19, 2021: InCarda Therapeutics announces enrollment of first U.S. patient in phase 2 INSTANT trial of InRhythm for treatment of atrial fibrillation

Nov 13, 2020: InCarda Therapeutics presents positive new data from phase 2 study of InRhythm in patients with paroxysmal atrial fibrillation at American Heart Association Scientific Sessions 2020

Sep 11, 2020: Daiichi Sankyo submits Supplemental Application in Japan for approval of partial changes in usage or dosage for Anticoagulant Edoxaban

Aug 31, 2020: New 12-month analysis data from ETNA-AF non-interventional study show low bleeding and ICH rates in frail and ageing AF patients on LIXIANA (edoxaban) during routine clinical care

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Atrial Fibrillation, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Atrial Fibrillation - Pipeline by AbbVie Inc, 2022
Atrial Fibrillation - Pipeline by Acesion Pharma Aps, 2022
Atrial Fibrillation - Pipeline by Aetas Pharma Co Ltd, 2022
Atrial Fibrillation - Pipeline by AnaBios Corp, 2022
Atrial Fibrillation - Pipeline by Anthos Therapeutics Inc, 2022
Atrial Fibrillation - Pipeline by ARCA biopharma Inc, 2022
Atrial Fibrillation - Pipeline by Armaron Bio Pty Ltd, 2022
Atrial Fibrillation - Pipeline by Bayer AG, 2022
Atrial Fibrillation - Pipeline by Bristol-Myers Squibb Co, 2022
Atrial Fibrillation - Pipeline by Chaperone Pharma BV, 2022
Atrial Fibrillation - Pipeline by Chong Kun Dang Pharmaceutical Corp, 2022
Atrial Fibrillation - Pipeline by Correvio Pharma Corp, 2022
Atrial Fibrillation - Pipeline by Daiichi Sankyo Co Ltd, 2022
Atrial Fibrillation - Pipeline by Espero BioPharma Inc, 2022
Atrial Fibrillation - Pipeline by FB HRS LLC, 2022
Atrial Fibrillation - Pipeline by G3 Pharmaceuticals Inc, 2022
Atrial Fibrillation - Pipeline by Hanmi Pharmaceuticals Co Ltd, 2022
Atrial Fibrillation - Pipeline by HUYA Bioscience International LLC, 2022
Atrial Fibrillation - Pipeline by Hyloris Pharmaceuticals SA, 2022
Atrial Fibrillation - Pipeline by InCarda Therapeutics Inc, 2022
Atrial Fibrillation - Pipeline by Inomagen Therapeutics Inc, 2022
Atrial Fibrillation - Pipeline by Merck & Co Inc, 2022
Atrial Fibrillation - Pipeline by Merz Pharma GmbH & Co KgaA, 2022
Atrial Fibrillation - Pipeline by Milestone Pharmaceuticals Inc, 2022

Atrial Fibrillation - Pipeline by Nissan Chemical Corp, 2022
Atrial Fibrillation - Pipeline by Novartis AG, 2022
Atrial Fibrillation - Pipeline by Rithim Biologics Inc, 2022
Atrial Fibrillation - Pipeline by The Geneva Biotech Center SA, 2022
Atrial Fibrillation - Pipeline by Toa Eiyo Ltd, 2022
Atrial Fibrillation - Pipeline by Verseon Corp, 2022
Atrial Fibrillation - Pipeline by Vivasc Therapeutics Inc, 2022
Atrial Fibrillation - Dormant Projects, 2022
Atrial Fibrillation - Dormant Projects, 2022 (Contd..1)
Atrial Fibrillation - Dormant Projects, 2022 (Contd..2)
Atrial Fibrillation - Discontinued Products, 2022
Atrial Fibrillation - Discontinued Products, 2022 (Contd..1)

List Of Figures

LIST OF FIGURES

Number of Products under Development for Atrial Fibrillation, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Atrial Fibrillation Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/ABA4BA6EDC03EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ABA4BA6EDC03EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

